MeSH term
Frequency | Condition_Probility | Adult | 221 | 0.0 |
Aged | 213 | 0.0 |
Aged, 80 and over | 91 | 0.0 |
Breast Neoplasms/*chemistry/pathology | 8 | 13.0 |
Female | 473 | 0.0 |
Humans | 545 | 0.0 |
Immunohistochemistry | 82 | 0.0 |
Middle Aged | 278 | 0.0 |
Prognosis | 167 | 2.0 |
RNA, Messenger/analysis | 9 | 0.0 |
Receptors, Estrogen/analysis | 87 | 25.0 |
Receptors, Progesterone/analysis | 89 | 36.0 |
Comparative Study | 80 | 0.0 |
Ligands | 8 | 0.0 |
Molecular Structure | 3 | 0.0 |
Receptors, Progesterone/*metabolism | 56 | 49.0 |
Research Support, Non-U.S. Gov't | 268 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 10 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 74 | 0.0 |
Microscopy, Electron | 6 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 12 | 2.0 |
Disease-Free Survival | 28 | 3.0 |
Hormone Antagonists/*therapeutic use | 2 | 18.0 |
Receptors, Estrogen/metabolism | 38 | 12.0 |
Receptors, Progesterone/metabolism | 46 | 23.0 |
Retrospective Studies | 31 | 0.0 |
Animals | 46 | 0.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Drug Screening Assays, Antitumor | 4 | 1.0 |
Estrogens/pharmacology | 2 | 2.0 |
Mice | 21 | 0.0 |
Tumor Cells, Cultured | 35 | 0.0 |
Apoptosis | 5 | 0.0 |
Breast Neoplasms/*genetics/metabolism/pathology | 3 | 5.0 |
Cell Division | 28 | 0.0 |
Keratin/metabolism | 2 | 1.0 |
Mitotic Index | 8 | 4.0 |
*Mutation | 2 | 0.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Phenotype | 8 | 0.0 |
Polymerase Chain Reaction/methods | 3 | 0.0 |
Polymorphism, Single-Stranded Conformational | 5 | 0.0 |
Protein p53/metabolism | 7 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 4 | 0.0 |
Vimentin/metabolism | 2 | 1.0 |
Age Factors | 21 | 0.0 |
Japan/epidemiology | 2 | 0.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Reproducibility of Results | 10 | 0.0 |
Sensitivity and Specificity | 9 | 0.0 |
Cohort Studies | 2 | 0.0 |
Combined Modality Therapy | 16 | 1.0 |
DNA, Neoplasm/analysis | 9 | 1.0 |
Follow-Up Studies | 38 | 1.0 |
Lymph Node Excision | 4 | 5.0 |
Mastectomy, Segmental | 3 | 17.0 |
Ploidies | 16 | 6.0 |
Radiotherapy Dosage | 2 | 1.0 |
Survival Rate | 23 | 1.0 |
Treatment Outcome | 26 | 0.0 |
Tumor Markers, Biological/*metabolism | 12 | 2.0 |
Antineoplastic Agents, Hormonal/*therapeutic use | 15 | 20.0 |
Breast Neoplasms/chemistry/*drug therapy | 3 | 75.0 |
English Abstract | 32 | 0.0 |
Breast Neoplasms/*metabolism/pathology | 18 | 9.0 |
Cathepsin D/metabolism | 3 | 7.0 |
Ki-67 Antigen/metabolism | 12 | 5.0 |
Prospective Studies | 20 | 0.0 |
Receptors, Cell Surface/metabolism | 2 | 0.0 |
Breast Neoplasms/chemistry/*pathology | 5 | 29.0 |
Ki-67 Antigen/analysis | 6 | 2.0 |
Neoplasm Staging | 33 | 1.0 |
Receptor, erbB-2/analysis | 6 | 6.0 |
Estrogen Antagonists/pharmacology | 7 | 7.0 |
Phenols/*pharmacology | 2 | 5.0 |
Protein Biosynthesis | 2 | 0.0 |
*Proteins | 7 | 1.0 |
Receptors, Progesterone/biosynthesis/drug effects | 2 | 66.0 |
Cell Nucleus/metabolism | 7 | 0.0 |
Endometrium/*metabolism | 4 | 4.0 |
Luteal Phase | 3 | 4.0 |
Progesterone/blood | 9 | 3.0 |
Time Factors | 29 | 0.0 |
Aromatase Inhibitors | 4 | 21.0 |
Enzyme Inhibitors/therapeutic use | 2 | 2.0 |
Estrogen Receptor Modulators/therapeutic use | 3 | 50.0 |
Mice, Nude | 20 | 1.0 |
Models, Biological | 4 | 0.0 |
Neoplasm Transplantation | 11 | 0.0 |
Proteins/metabolism | 4 | 0.0 |
Receptors, Estrogen/drug effects/metabolism | 4 | 28.0 |
Receptors, Progesterone/drug effects/metabolism | 5 | 55.0 |
Tamoxifen/therapeutic use | 19 | 30.0 |
Transplantation, Heterologous | 10 | 1.0 |
*Aromatase Inhibitors | 3 | 17.0 |
Chemotherapy, Adjuvant | 20 | 8.0 |
Enzyme Inhibitors/*therapeutic use | 3 | 3.0 |
Menopause | 49 | 22.0 |
Nitriles/therapeutic use | 3 | 75.0 |
Triazoles/therapeutic use | 3 | 100.0 |
Antineoplastic Agents/*therapeutic use | 7 | 1.0 |
Breast Neoplasms/*drug therapy | 13 | 19.0 |
Double-Blind Method | 5 | 0.0 |
Nitriles/*therapeutic use | 6 | 100.0 |
Postmenopause | 20 | 10.0 |
Preoperative Care | 3 | 1.0 |
Tamoxifen/*therapeutic use | 36 | 45.0 |
Triazoles/*therapeutic use | 6 | 85.0 |
Male | 57 | 0.0 |
Receptors, Estrogen/*analysis | 131 | 50.0 |
Receptors, Progesterone/*analysis | 149 | 69.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 6 | 1.0 |
Estrogen Receptor beta | 6 | 7.0 |
Immunohistochemistry/methods | 6 | 0.0 |
Lymphatic Metastasis | 51 | 5.0 |
Receptors, Estrogen/*genetics/metabolism | 5 | 21.0 |
Protein p53/*analysis | 6 | 3.0 |
Multivariate Analysis | 32 | 2.0 |
Radioligand Assay | 8 | 1.0 |
Receptors, Progesterone/drug effects | 5 | 55.0 |
Structure-Activity Relationship | 5 | 0.0 |
Antibodies, Monoclonal | 10 | 0.0 |
Biopsy, Needle | 10 | 2.0 |
Breast Neoplasms/*pathology/surgery | 4 | 25.0 |
Keratin/analysis | 3 | 1.0 |
Premenopause | 10 | 10.0 |
Amino Acid Sequence | 3 | 0.0 |
Base Sequence | 12 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Molecular Sequence Data | 10 | 0.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Tissue Distribution | 7 | 0.0 |
Body Mass Index | 3 | 0.0 |
Breast Neoplasms/*chemistry | 18 | 25.0 |
Estradiol/blood | 8 | 1.0 |
Menstruation | 5 | 8.0 |
Obesity/complications | 2 | 4.0 |
Survival Analysis | 28 | 1.0 |
Analysis of Variance | 10 | 0.0 |
Disease Progression | 13 | 0.0 |
Flow Cytometry | 18 | 0.0 |
Neoplasm Proteins/*analysis | 16 | 4.0 |
Plasminogen Activator Inhibitor 1/*analysis | 2 | 16.0 |
Proportional Hazards Models | 13 | 1.0 |
Urinary Plasminogen Activator/*analysis | 2 | 22.0 |
Cyclophosphamide/administration & dosage | 6 | 2.0 |
Fluorouracil/administration & dosage | 6 | 4.0 |
Mastectomy | 11 | 16.0 |
Methotrexate/administration & dosage | 7 | 7.0 |
Receptor, erbB-2/metabolism | 7 | 4.0 |
Receptors, Estrogen/*metabolism | 58 | 28.0 |
Breast Neoplasms/metabolism/*pathology | 6 | 6.0 |
Lymph Nodes/pathology | 13 | 4.0 |
*Muscle Proteins | 2 | 0.0 |
Thymidine/metabolism | 6 | 1.0 |
Cell Division/drug effects | 18 | 0.0 |
Estradiol/*analogs & derivatives/pharmacology | 5 | 11.0 |
Estrogen Receptor Modulators/pharmacology | 2 | 9.0 |
Estrogen Receptor alpha | 12 | 5.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
Receptors, Estrogen/genetics/metabolism | 2 | 6.0 |
Receptors, Progesterone/genetics/metabolism | 4 | 36.0 |
Alleles | 5 | 0.0 |
Exons | 5 | 0.0 |
Heterozygote | 5 | 0.0 |
Odds Ratio | 3 | 0.0 |
Ovarian Neoplasms/*genetics | 2 | 0.0 |
Polymerase Chain Reaction | 15 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Receptors, Estrogen/biosynthesis | 9 | 20.0 |
Receptors, Progesterone/*genetics | 6 | 27.0 |
Risk Factors | 11 | 0.0 |
Breast Neoplasms/drug therapy/*metabolism/pathology/surgery | 2 | 66.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Ki-67 Antigen/biosynthesis | 4 | 5.0 |
Receptors, Progesterone/biosynthesis | 8 | 25.0 |
Isoenzymes/*biosynthesis | 2 | 3.0 |
Neoplasm Metastasis | 22 | 2.0 |
Paraffin Embedding | 7 | 2.0 |
Prostaglandin-Endoperoxide Synthase/*biosynthesis | 2 | 4.0 |
Receptor, erbB-2/biosynthesis | 3 | 12.0 |
Breast Neoplasms/*pathology | 13 | 6.0 |
Incidence | 2 | 0.0 |
Tumor Markers, Biological/analysis | 10 | 1.0 |
Ki-67 Antigen/*metabolism | 3 | 6.0 |
Meningeal Neoplasms/*metabolism/pathology | 2 | 25.0 |
Meningioma/*metabolism/pathology | 2 | 11.0 |
Carcinoma, Ductal, Breast/*metabolism/pathology | 2 | 10.0 |
Protein p53/*metabolism | 4 | 0.0 |
Antineoplastic Agents, Hormonal/pharmacology | 2 | 4.0 |
Cell Nucleus/ultrastructure | 2 | 1.0 |
Cytoplasm/ultrastructure | 2 | 3.0 |
Uterine Neoplasms/metabolism/*pathology | 2 | 33.0 |
Breast Neoplasms | 3 | 1.0 |
Cells, Cultured | 5 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 4 | 0.0 |
Receptors, Progesterone/genetics | 7 | 36.0 |
Reverse Transcriptase Polymerase Chain Reaction | 11 | 0.0 |
Immunoenzyme Techniques | 48 | 1.0 |
Pregnancy | 11 | 0.0 |
Reference Values | 5 | 0.0 |
Estradiol/*blood | 2 | 1.0 |
Menstrual Cycle | 5 | 4.0 |
Progesterone/*blood | 3 | 7.0 |
Prostatic Neoplasms/metabolism/*pathology | 2 | 2.0 |
Tumor Markers, Biological/metabolism | 7 | 1.0 |
*Neoplasm Recurrence, Local | 5 | 11.0 |
Protein p53/biosynthesis | 3 | 2.0 |
Aneuploidy | 5 | 2.0 |
Estrogens | 2 | 8.0 |
Genes, p53 | 2 | 0.0 |
Neoplasm Invasiveness | 12 | 1.0 |
Progesterone | 2 | 66.0 |
Tumor Markers, Biological/*analysis | 32 | 3.0 |
Actuarial Analysis | 3 | 4.0 |
*S Phase | 5 | 7.0 |
Urinary Plasminogen Activator/*metabolism | 3 | 8.0 |
Gene Expression | 6 | 0.0 |
Gene Expression Regulation, Neoplastic | 12 | 0.0 |
Receptors, Estrogen/*biosynthesis/genetics | 2 | 33.0 |
Mutation | 7 | 0.0 |
Protein p53/*biosynthesis | 2 | 1.0 |
Protein p53/analysis | 11 | 3.0 |
Binding, Competitive | 11 | 0.0 |
Logistic Models | 8 | 1.0 |
Predictive Value of Tests | 29 | 1.0 |
Breast Neoplasms/chemistry/*pathology/surgery | 2 | 28.0 |
Neoplasm Proteins/analysis | 6 | 1.0 |
Carcinoma, Ductal, Breast/metabolism/pathology | 2 | 9.0 |
Cathepsin D/*metabolism | 3 | 20.0 |
Statistics | 4 | 0.0 |
*Antiretroviral Therapy, Highly Active | 4 | 1.0 |
Developing Countries | 4 | 5.0 |
Tuberculosis/epidemiology/*prevention & control | 4 | 40.0 |
Carcinoma/*metabolism/pathology | 2 | 3.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Endometrium/metabolism | 3 | 5.0 |
Estrogens/*metabolism | 5 | 9.0 |
Tumor Markers, Biological | 4 | 0.0 |
Breast Neoplasms/*metabolism | 29 | 9.0 |
Cell Line, Tumor | 7 | 0.0 |
Cytoplasm/metabolism | 6 | 0.0 |
Cytosol/metabolism | 14 | 2.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Tumor Markers, Biological/*blood | 2 | 0.0 |
Breast Neoplasms/genetics/metabolism/*pathology | 2 | 5.0 |
Carcinoma, Ductal, Breast/genetics/metabolism/*pathology | 2 | 50.0 |
DNA, Neoplasm/*analysis | 10 | 5.0 |
Genetic Markers | 5 | 0.0 |
Necrosis | 2 | 0.0 |
Neoplasm Proteins/*metabolism | 7 | 1.0 |
*Ploidies | 5 | 7.0 |
Estrogens/metabolism | 3 | 3.0 |
Diagnosis, Differential | 2 | 0.0 |
Goserelin/therapeutic use | 2 | 33.0 |
Ovariectomy | 4 | 3.0 |
Estradiol/metabolism | 5 | 5.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Endometrial Neoplasms/*metabolism/pathology | 2 | 6.0 |
Menstrual Cycle/*physiology | 2 | 3.0 |
Quality Control | 2 | 1.0 |
Reference Standards | 2 | 0.0 |
Binding Sites | 4 | 0.0 |
In Vitro | 2 | 0.0 |
Carcinoma, Ductal, Breast/metabolism | 2 | 22.0 |
Cell Nucleus/*metabolism | 4 | 0.0 |
Antineoplastic Agents, Hormonal/administration & dosage/*therapeutic use | 3 | 37.0 |
Neoplasm Recurrence, Local | 10 | 2.0 |
Tamoxifen/administration & dosage/*therapeutic use | 4 | 50.0 |
Denmark | 4 | 2.0 |
*Menstrual Cycle | 3 | 4.0 |
BRCA2 Protein | 3 | 0.0 |
Microsatellite Repeats | 3 | 0.0 |
Neoplasm Proteins/*genetics | 4 | 0.0 |
Transcription Factors/genetics | 3 | 0.0 |
Breast Neoplasms/*drug therapy/pathology | 3 | 7.0 |
Recurrence | 5 | 0.0 |
S Phase | 5 | 1.0 |
Biological Markers/analysis | 3 | 0.0 |
*Biopsy, Needle | 2 | 5.0 |
*Immunohistochemistry | 3 | 3.0 |
Receptor, erbB-2/*analysis | 4 | 4.0 |
Progesterone/metabolism | 7 | 8.0 |
Breast Neoplasms/*genetics/*metabolism | 4 | 10.0 |
DNA Probes | 2 | 0.0 |
RNA, Messenger/*genetics | 3 | 0.0 |
Breast Neoplasms/*chemistry/genetics | 3 | 23.0 |
Cyclin D1/*metabolism | 2 | 3.0 |
Breast Neoplasms/*genetics | 9 | 1.0 |
Chromosome Mapping | 5 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Breast Neoplasms/*genetics/pathology | 6 | 2.0 |
Breast Neoplasms/*chemistry/mortality/pathology | 5 | 25.0 |
Pilot Projects | 5 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis | 4 | 3.0 |
Receptors, Progesterone/*biosynthesis | 8 | 50.0 |
Radiotherapy, Adjuvant | 2 | 2.0 |
Antineoplastic Agents, Hormonal/*pharmacology | 2 | 3.0 |
Estradiol/pharmacology | 13 | 4.0 |
*Gene Expression Regulation, Neoplastic | 6 | 0.0 |
*Protein Biosynthesis | 2 | 0.0 |
Tamoxifen/pharmacology | 13 | 13.0 |
Mitoxantrone/administration & dosage | 3 | 11.0 |
Neoadjuvant Therapy | 4 | 10.0 |
Tamoxifen/administration & dosage | 6 | 33.0 |
Adenocarcinoma/*metabolism/pathology | 3 | 2.0 |
Cell Cycle | 2 | 0.0 |
Breast Neoplasms/*drug therapy/metabolism | 6 | 22.0 |
Remission Induction | 4 | 0.0 |
Carcinoma, Ductal, Breast/metabolism/*pathology | 2 | 25.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Karyotyping | 5 | 0.0 |
Receptors, Progesterone/genetics/*metabolism | 4 | 33.0 |
Breast Neoplasms/*metabolism/physiopathology | 3 | 75.0 |
Antineoplastic Agents, Hormonal/therapeutic use | 3 | 6.0 |
Breast Neoplasms/*therapy | 3 | 11.0 |
Fluorouracil/therapeutic use | 4 | 8.0 |
Methotrexate/therapeutic use | 3 | 4.0 |
Adolescent | 12 | 0.0 |
Epithelium/metabolism | 3 | 0.0 |
Rats | 17 | 0.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Obesity/*metabolism | 2 | 2.0 |
Risk Assessment | 3 | 0.0 |
Breast Neoplasms/genetics/*metabolism/pathology | 2 | 4.0 |
Fixatives | 2 | 2.0 |
Flow Cytometry/*methods | 2 | 0.0 |
Formaldehyde | 3 | 3.0 |
Receptors, Estrogen/*biosynthesis | 6 | 26.0 |
Mammary Neoplasms, Experimental/*pathology | 2 | 12.0 |
Breast Neoplasms/*metabolism/*pathology | 2 | 5.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 3 | 1.0 |
Ki-67 Antigen | 6 | 2.0 |
Nuclear Proteins/analysis | 2 | 1.0 |
Receptors, Androgen/*analysis | 7 | 10.0 |
Sex Characteristics | 2 | 0.0 |
Cell Cycle/drug effects | 3 | 0.0 |
Cell Division/*drug effects | 5 | 1.0 |
Progesterone/pharmacology | 4 | 3.0 |
Transfection | 3 | 0.0 |
Genes, p53/*genetics | 2 | 0.0 |
Breast Neoplasms/*genetics/metabolism | 4 | 3.0 |
Cyclin D1/metabolism | 3 | 2.0 |
Genes, BRCA1/*genetics | 2 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
*Chromosomes, Human, Pair 11 | 5 | 0.0 |
Gene Frequency | 3 | 0.0 |
Polymorphism, Genetic | 5 | 0.0 |
Chromatography, Gel | 2 | 0.0 |
Estrogen Antagonists/*metabolism | 2 | 33.0 |
Protein Binding | 3 | 0.0 |
Breast Neoplasms/*genetics/*pathology | 2 | 3.0 |
Regression Analysis | 7 | 0.0 |
Proteins/*metabolism | 2 | 0.0 |
Receptors, Androgen/metabolism | 3 | 7.0 |
Receptors, Steroid/*metabolism | 5 | 9.0 |
Antineoplastic Agents/therapeutic use | 3 | 1.0 |
Cell Proliferation | 2 | 1.0 |
Statistics, Nonparametric | 2 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Neoplasms/*genetics | 2 | 0.0 |
Follicle Stimulating Hormone/blood | 5 | 0.0 |
Luteinizing Hormone/blood | 4 | 0.0 |
Menopause/*physiology | 2 | 12.0 |
Breast Neoplasms/genetics/*metabolism | 5 | 8.0 |
Receptor, erbB-2/*metabolism | 2 | 1.0 |
Breast/metabolism | 3 | 3.0 |
Cell Nucleus/chemistry | 4 | 2.0 |
Cytosol/chemistry | 6 | 11.0 |
Cathepsin D/*analysis | 3 | 15.0 |
Proteins/*analysis | 2 | 1.0 |
Receptors, Steroid/*analysis | 9 | 37.0 |
Antineoplastic Agents/*toxicity | 2 | 3.0 |
Cattle | 3 | 0.0 |
Cell Line | 20 | 0.0 |
Biological Markers | 3 | 0.0 |
Staining and Labeling | 4 | 0.0 |
Receptors, Estrogen/*analysis/genetics | 4 | 66.0 |
Receptors, Progesterone/*analysis/genetics | 3 | 60.0 |
*Neovascularization, Pathologic | 2 | 0.0 |
Probability | 2 | 0.0 |
Japan | 5 | 0.0 |
Case-Control Studies | 4 | 0.0 |
Confidence Intervals | 2 | 0.0 |
Haplotypes | 2 | 0.0 |
Linkage Disequilibrium | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Body Weight | 2 | 0.0 |
Estrogen Antagonists/*therapeutic use | 4 | 20.0 |
Ki-67 Antigen/*analysis | 3 | 4.0 |
Receptors, Cell Surface/*analysis | 2 | 1.0 |
Child | 2 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
RNA, Neoplasm/genetics | 3 | 0.0 |
Receptors, Estrogen/*genetics | 3 | 3.0 |
Sequence Deletion | 3 | 0.0 |
Observer Variation | 3 | 2.0 |
Drug Resistance | 5 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
DNA, Neoplasm/genetics | 5 | 0.0 |
*Gene Amplification | 4 | 1.0 |
Breast Neoplasms/metabolism | 2 | 1.0 |
Receptors, Estrogen/*drug effects/metabolism | 3 | 37.0 |
Breast Neoplasms/*metabolism/mortality/pathology | 2 | 20.0 |
Tamoxifen/*metabolism | 2 | 22.0 |
Cell Division/physiology | 4 | 0.0 |
Receptors, Estradiol/*metabolism | 3 | 27.0 |
Cell Culture Techniques/methods | 2 | 0.0 |
Gonanes/pharmacology | 2 | 33.0 |
Ki-67 Antigen/analysis/biosynthesis | 2 | 40.0 |
Receptors, Progesterone/analysis/*biosynthesis | 2 | 40.0 |
DNA/metabolism | 3 | 0.0 |
Receptors, Progesterone/*drug effects/metabolism | 3 | 100.0 |
Receptors, Estrogen/genetics/*metabolism | 2 | 5.0 |
Drug Synergism | 2 | 0.0 |
Receptors, Estrogen/*drug effects | 6 | 42.0 |
Breast Neoplasms/*drug therapy/mortality | 2 | 40.0 |
Receptors, Estrogen | 3 | 17.0 |
Receptors, Progesterone | 2 | 20.0 |
Breast Neoplasms/*chemistry/diagnosis | 2 | 50.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 2 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Breast Neoplasms/chemistry/*genetics | 3 | 16.0 |
*Chromosome Aberrations | 2 | 0.0 |
Dyes | 2 | 1.0 |
Biopsy | 11 | 0.0 |
RNA, Neoplasm/analysis | 3 | 1.0 |
Receptor, Epidermal Growth Factor/*metabolism | 3 | 0.0 |
Receptors, Estradiol/metabolism | 3 | 37.0 |
Estradiol/*analysis | 2 | 40.0 |
Radioimmunoassay | 2 | 0.0 |
Adenocarcinoma/*chemistry/pathology | 3 | 6.0 |
Up-Regulation | 3 | 0.0 |
Adenocarcinoma/metabolism | 2 | 2.0 |
Receptors, Androgen/analysis | 7 | 24.0 |
Testosterone/blood | 4 | 0.0 |
Registries | 3 | 1.0 |
Carcinoma/*metabolism | 3 | 3.0 |
Endometrial Neoplasms/*metabolism | 3 | 9.0 |
Tumor Cells, Cultured/drug effects | 5 | 0.0 |
*Chromosome Deletion | 2 | 0.0 |
Epirubicin/administration & dosage | 3 | 8.0 |
Disease Models, Animal | 2 | 0.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Estradiol/*pharmacology | 9 | 3.0 |
Breast Neoplasms/*drug therapy/*metabolism | 5 | 26.0 |
Drug Administration Schedule | 4 | 0.0 |
*Drug Resistance, Neoplasm | 3 | 1.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Frozen Sections | 2 | 2.0 |
Axilla | 6 | 9.0 |
Treatment Failure | 2 | 0.0 |
Carcinoma/chemistry/*pathology | 2 | 20.0 |
Biopsy, Fine-Needle | 2 | 10.0 |
False Negative Reactions | 3 | 2.0 |
Receptor, erbB-2/*biosynthesis | 2 | 4.0 |
DNA Primers/chemistry | 2 | 0.0 |
Proto-Oncogenes | 2 | 1.0 |
Breast Neoplasms/*metabolism/ultrastructure | 2 | 33.0 |
Receptors, Cell Surface/*metabolism | 4 | 0.0 |
Receptors, Progesterone/*biosynthesis/drug effects | 2 | 100.0 |
Drug Therapy, Combination | 4 | 0.0 |
Megestrol Acetate | 4 | 33.0 |
Tamoxifen/*pharmacology/therapeutic use | 2 | 40.0 |
Estrogens/*physiology | 3 | 7.0 |
Tamoxifen/adverse effects/*therapeutic use | 2 | 33.0 |
Antigens, Neoplasm/*analysis | 2 | 0.0 |
Nuclear Proteins/*analysis | 3 | 1.0 |
Chi-Square Distribution | 3 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 12 | 1.0 |
Meningeal Neoplasms/*pathology | 2 | 20.0 |
Meningioma/*pathology | 2 | 28.0 |
Estrogens/*analysis | 3 | 75.0 |
Blotting, Western | 7 | 0.0 |
Genes, erbB-2 | 3 | 3.0 |
Cathepsin D/analysis | 2 | 5.0 |
Receptor, Epidermal Growth Factor/analysis | 6 | 3.0 |
Brain/pathology | 3 | 0.0 |
Brain Edema/pathology/surgery | 2 | 100.0 |
Meningeal Neoplasms/*pathology/surgery | 2 | 66.0 |
Meningioma/*pathology/surgery | 2 | 66.0 |
Neoplasms, Hormone-Dependent/*pathology/surgery | 2 | 100.0 |
Immunoassay | 2 | 0.0 |
Neoplasm Recurrence, Local/chemistry | 2 | 33.0 |
African Continental Ancestry Group | 2 | 0.0 |
Myometrium/*chemistry | 2 | 22.0 |
Life Tables | 2 | 1.0 |
Gene Amplification | 5 | 0.0 |
Genes, myc | 2 | 0.0 |
Estrogen Antagonists/*pharmacology | 4 | 5.0 |
Antigens, CD/analysis | 2 | 0.0 |
Breast Neoplasms/*chemistry/genetics/pathology | 2 | 33.0 |
Molecular Weight | 4 | 0.0 |
Blotting, Southern | 3 | 0.0 |
Neoplasm Recurrence, Local/*prevention & control | 3 | 21.0 |
Mifepristone/pharmacology | 2 | 2.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Genotype | 2 | 0.0 |
Receptor, Epidermal Growth Factor/*analysis/genetics | 2 | 5.0 |
Receptor, erbB-2 | 8 | 4.0 |
Breast Neoplasms/*chemistry/mortality | 3 | 37.0 |
Carrier Proteins/*analysis | 2 | 2.0 |
Pregnenediones/pharmacology | 2 | 18.0 |
Promegestone/pharmacology | 2 | 12.0 |
Receptor, Epidermal Growth Factor/*analysis | 5 | 1.0 |
Bone Neoplasms/secondary | 5 | 11.0 |
Breast Neoplasms/*enzymology | 4 | 6.0 |
Tritium/diagnostic use | 5 | 4.0 |
Breast/*chemistry | 2 | 8.0 |
Epithelium/chemistry | 2 | 1.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Neoplasms, Hormone-Dependent/*pathology | 2 | 11.0 |
Tamoxifen/*administration & dosage | 2 | 33.0 |
Carcinoma, Ductal, Breast/*metabolism | 2 | 18.0 |
Fibrocystic Breast Disease/metabolism | 2 | 33.0 |
Tamoxifen/*pharmacology | 5 | 7.0 |
Uterus/metabolism | 2 | 5.0 |
Oncogene Proteins, Viral/*analysis | 2 | 50.0 |
Breast/*pathology | 2 | 11.0 |
Kinetics | 10 | 0.0 |
S Phase/physiology | 2 | 2.0 |
Progestins/*pharmacology | 2 | 8.0 |
Isoelectric Focusing | 5 | 0.0 |
Receptors, Estrogen/drug effects | 3 | 23.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Receptors, Somatomedin | 2 | 4.0 |
Breast Neoplasms/*drug therapy/*metabolism/pathology | 2 | 50.0 |
*Aneuploidy | 2 | 2.0 |
*Flow Cytometry | 2 | 1.0 |
Cytosol/*chemistry | 2 | 22.0 |
Charcoal | 13 | 50.0 |
Dextrans | 13 | 27.0 |
Methods | 6 | 2.0 |
Estrogens/*pharmacology | 2 | 2.0 |
Neoplasms, Hormone-Dependent/*metabolism | 3 | 23.0 |
Breast/pathology | 4 | 13.0 |
Breast Neoplasms/diagnosis/*metabolism/pathology | 2 | 100.0 |
Receptors, Estradiol/analysis | 3 | 27.0 |
Italy | 2 | 0.0 |
Immunohistochemistry/*methods | 3 | 3.0 |
Rats, Inbred Strains | 7 | 0.0 |
Tritium | 3 | 1.0 |
Receptors, Estrogen/physiology | 2 | 7.0 |
Breast Neoplasms/*drug therapy/metabolism/surgery | 2 | 66.0 |
Receptors, Estradiol/*analysis | 3 | 37.0 |
Tissue Preservation | 2 | 6.0 |
Receptors, Progesterone/*analysis/immunology | 3 | 75.0 |
Random Allocation | 5 | 1.0 |
Endometrial Hyperplasia/*metabolism/pathology | 2 | 28.0 |
Soft Tissue Neoplasms/secondary | 2 | 50.0 |
*Proto-Oncogenes | 3 | 0.0 |
Antibodies, Monoclonal/*diagnostic use | 4 | 1.0 |
Neoplasms, Hormone-Dependent/chemistry | 3 | 75.0 |
Randomized Controlled Trials | 2 | 0.0 |
Menopause/*metabolism | 2 | 16.0 |
Receptors, Progesterone/*drug effects | 5 | 62.0 |
Antibodies | 2 | 0.0 |
Receptors, Prolactin/*analysis | 2 | 25.0 |
Blotting, Northern | 4 | 0.0 |
RNA Probes | 2 | 1.0 |
Medroxyprogesterone 17-Acetate | 4 | 13.0 |
Uterine Neoplasms/*metabolism/pathology | 2 | 13.0 |
Breast Neoplasms/*analysis | 16 | 41.0 |
Breast Neoplasms/*pathology/therapy | 2 | 50.0 |
Breast Neoplasms/*analysis/drug therapy | 4 | 80.0 |
Oncogenes | 2 | 0.0 |
Evaluation Studies | 2 | 0.0 |
Mastectomy, Modified Radical | 2 | 25.0 |
Hormones/therapeutic use | 5 | 29.0 |
Breast Neoplasms/analysis/*pathology | 3 | 60.0 |
Breast Neoplasms/*analysis/pathology | 8 | 40.0 |
Cytosol/analysis | 12 | 36.0 |
Clinical Trials | 4 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Nandrolone/*analogs & derivatives/chemical synthesis/metabolism | 2 | 100.0 |
Swine | 2 | 0.0 |
Breast Neoplasms/*analysis/mortality/surgery | 2 | 100.0 |
Breast Neoplasms/analysis | 3 | 42.0 |
Rabbits | 3 | 0.0 |
Uterus/analysis | 4 | 57.0 |
Endometrium/analysis | 2 | 40.0 |
Myometrium/analysis | 2 | 40.0 |
Lactalbumin/analysis | 2 | 66.0 |
Breast Neoplasms/*analysis/mortality/pathology | 3 | 100.0 |
Promegestone/metabolism | 4 | 33.0 |
Temperature | 3 | 0.0 |
Histocytochemistry | 3 | 0.0 |
Carcinoma/*analysis/pathology | 2 | 33.0 |
Breast Neoplasms/analysis/*drug therapy | 2 | 100.0 |
Megestrol/*analogs & derivatives/therapeutic use | 2 | 50.0 |
*Receptors, Steroid | 2 | 9.0 |
Cell Nucleus/analysis | 4 | 19.0 |
Neoplasms, Hormone-Dependent/analysis | 2 | 50.0 |
Breast Neoplasms/metabolism/*therapy | 2 | 40.0 |
*Luteal Phase | 2 | 9.0 |
Breast Neoplasms/*analysis/drug therapy/mortality | 2 | 100.0 |
Cyclophosphamide/therapeutic use | 2 | 2.0 |
Interphase | 3 | 1.0 |
Proteins/analysis | 2 | 1.0 |
Centrifugation, Density Gradient | 3 | 0.0 |
Estradiol/analysis | 2 | 10.0 |
Iodine Radioisotopes/diagnostic use | 3 | 0.0 |
Cytoplasm/analysis | 2 | 9.0 |
Pregnenediones/metabolism | 2 | 40.0 |
Progesterone Congeners/metabolism | 2 | 50.0 |
Endometrium/*analysis | 3 | 60.0 |
Breast Neoplasms/*analysis/drug therapy/pathology | 2 | 66.0 |
Peroxidases/*metabolism | 2 | 7.0 |
*Menstruation | 2 | 5.0 |
Castration | 6 | 13.0 |
Breast Neoplasms/drug therapy/*metabolism/mortality | 2 | 100.0 |
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage | 2 | 3.0 |
Mitomycin | 2 | 4.0 |
Mitomycins/administration & dosage | 2 | 11.0 |
Breast Neoplasms/analysis/genetics/*pathology | 2 | 100.0 |
Receptors, Estradiol | 3 | 100.0 |
Breast Neoplasms/*analysis/therapy | 2 | 100.0 |
Adsorption | 2 | 1.0 |
United States | 2 | 0.0 |
Breast Neoplasms/*drug therapy/*pathology | 2 | 25.0 |
Prolactin/blood | 3 | 0.0 |
Carcinoma, Intraductal, Noninfiltrating/*metabolism | 2 | 25.0 |
Immunoenzyme Techniques/methods | 2 | 12.0 |
Hypophysectomy | 2 | 3.0 |
*Receptors, Estrogen | 4 | 30.0 |
*Receptors, Progesterone | 4 | 100.0 |
*Transcription Factors | 2 | 0.0 |
